Impact of common comorbidities on antimicrobial consumption and mortality amongst critically ill COVID-19 patients : A retrospective two center study in Saudi Arabia
© 2023 The Author(s)..
Objectives: To determine the association between common comorbidities, ICU mortality and antimicrobial consumption among critically ill COVID 19 patients in Saudi Arabia.
Methods: A retrospective observational study of patients admitted to the ICU from March 1st, 2020, through August 31st, 2021. We excluded patients who stayed <24 h in the ICU and with no confirmed COVID-19 PCR testing.
Results: Of the 976 screened ICU patients, 848 were included. While there was no difference in mortality between patients with and without comorbidities, those with at least one comorbidity had a higher severity of illness (p = 0.013). Compared to survivors, non-survivors were more likely to require mechanical ventilation and vasopressor support (P < 0.001). Almost all patients received at least one antimicrobial therapy. Predictors independently associated with ICU mortality were: older age (adjusted odds ratio [AOR], 1.03; 95% confidence interval [CI], 1.01-1.04), vancomycin use (AOR, 2.69; 95% [CI], 1.65-4.37), linezolid use (AOR, 2.65; 95% [CI], 1.65-4.04), sepsis or septic shock (AOR, 6.39; 95% [CI], 3.68-11.08), Acute Kidney Injury (AKI) (AOR, 2.51; 95% [CI], 1.61-3.92) and Acute Respiratory Distress Syndrome (ARDS) (AOR, 2.03; 95% [CI], 1.61-3.92).
Conclusion: Older age, vancomycin and linezolid use, sepsis/septic shock, AKI, and ARDS were negative prognostic factors in critically ill COVID-19 patients. More studies are needed to evaluate the outcomes of survived critically ill patients in relation to their vaccination status.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
Clinical infection in practice - 19(2023) vom: 02. Juli, Seite 100229 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
AlQadheeb, Nada [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Revised 17.05.2023 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.clinpr.2023.100229 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM356718050 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM356718050 | ||
| 003 | DE-627 | ||
| 005 | 20231226071047.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.clinpr.2023.100229 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1189.xml |
| 035 | |a (DE-627)NLM356718050 | ||
| 035 | |a (NLM)37168925 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a AlQadheeb, Nada |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Impact of common comorbidities on antimicrobial consumption and mortality amongst critically ill COVID-19 patients |b A retrospective two center study in Saudi Arabia |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 17.05.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2023 The Author(s). | ||
| 520 | |a Objectives: To determine the association between common comorbidities, ICU mortality and antimicrobial consumption among critically ill COVID 19 patients in Saudi Arabia | ||
| 520 | |a Methods: A retrospective observational study of patients admitted to the ICU from March 1st, 2020, through August 31st, 2021. We excluded patients who stayed <24 h in the ICU and with no confirmed COVID-19 PCR testing | ||
| 520 | |a Results: Of the 976 screened ICU patients, 848 were included. While there was no difference in mortality between patients with and without comorbidities, those with at least one comorbidity had a higher severity of illness (p = 0.013). Compared to survivors, non-survivors were more likely to require mechanical ventilation and vasopressor support (P < 0.001). Almost all patients received at least one antimicrobial therapy. Predictors independently associated with ICU mortality were: older age (adjusted odds ratio [AOR], 1.03; 95% confidence interval [CI], 1.01-1.04), vancomycin use (AOR, 2.69; 95% [CI], 1.65-4.37), linezolid use (AOR, 2.65; 95% [CI], 1.65-4.04), sepsis or septic shock (AOR, 6.39; 95% [CI], 3.68-11.08), Acute Kidney Injury (AKI) (AOR, 2.51; 95% [CI], 1.61-3.92) and Acute Respiratory Distress Syndrome (ARDS) (AOR, 2.03; 95% [CI], 1.61-3.92) | ||
| 520 | |a Conclusion: Older age, vancomycin and linezolid use, sepsis/septic shock, AKI, and ARDS were negative prognostic factors in critically ill COVID-19 patients. More studies are needed to evaluate the outcomes of survived critically ill patients in relation to their vaccination status | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Comorbidities | |
| 650 | 4 | |a Intensive care unit | |
| 650 | 4 | |a Mortality | |
| 650 | 4 | |a Saudi Arabia | |
| 700 | 1 | |a AlMubayedh, Hanine |e verfasserin |4 aut | |
| 700 | 1 | |a AlBadrani, Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a Salam, Abdul |e verfasserin |4 aut | |
| 700 | 1 | |a AlOmar, Mukhtar |e verfasserin |4 aut | |
| 700 | 1 | |a AlAswad, Ahmed |e verfasserin |4 aut | |
| 700 | 1 | |a AlMualim, Mohammed |e verfasserin |4 aut | |
| 700 | 1 | |a AlQamariat, Zahra |e verfasserin |4 aut | |
| 700 | 1 | |a AlHubail, Rasheed |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical infection in practice |d 2019 |g 19(2023) vom: 02. Juli, Seite 100229 |w (DE-627)NLM30486448X |x 2590-1702 |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2023 |g day:02 |g month:07 |g pages:100229 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.clinpr.2023.100229 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2023 |b 02 |c 07 |h 100229 | ||